Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd.: GLP-1 import refusal records

Has FDA refused imports of GLP-1 products from Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd.?

Yes. FDA’s import refusal records list 1 refused shipment line declared as made by Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd. (China) whose FDA product code names semaglutide, on Jul 26, 2023. None of them carries a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.

Country
China
City in FDA records
Mudu, Suzhou
FEI numbers on the lines
3006529992
Refused lines
1
Lines with an Import Alert 66-80 API or powder code
0
Drugs named in the product codes
Semaglutide
Refusal dates
Jul 26, 2023

The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.

Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd. is on it.

Refused shipment lines

FDA refusal chargesShipment ID
Jul 26, 2023China61PIY72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).

FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.
SCS-9080969-3/11/1

FDA refusal charges on these lines

A line can carry several charges. Text is FDA’s charge statement, verbatim.

NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).1
FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.1
UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).1

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.

1 line from FDA files read Nov 15, 2026.